Intellia Therapeutics Inc is trading about 5% down today around the mid-$12s, extending a decline following its recent quarterly update and equity financing.
- Investors are weighing modest collaboration revenue and persistent cash burn against the overhang from April's $180 million stock offering.
- Markets are reassessing timelines and risks for late-stage CRISPR programs despite earlier positive Phase 3 data.
- The company has successfully extended its cash runway into 2028, providing a long-term buffer for its clinical development.